Dr. Costa on Biomarkers Beyond PD-L1 for Immunotherapy in NSCLC – OncLive
OncLive |
Dr. Costa on Biomarkers Beyond PD-L1 for Immunotherapy in NSCLC
OncLive The presence of PD-L1 expression, even at the highest level, doesn't necessarily predict a 100% response rate to immunotherapy, he says. Researchers are aware that there needs to be more refinements and better patient selection to determine who would … |
